Syros Pharmaceuticals Inc (SYRS) Director Buys $1,999,999.20 in Stock
Syros Pharmaceuticals Inc (NASDAQ:SYRS) Director Srinivas Akkaraju bought 209,424 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were bought at an average price of $9.55 per share, for a total transaction of $1,999,999.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Srinivas Akkaraju also recently made the following trade(s):
- On Thursday, December 14th, Srinivas Akkaraju bought 109,774 shares of Syros Pharmaceuticals stock. The shares were bought at an average price of $9.03 per share, for a total transaction of $991,259.22.
Shares of Syros Pharmaceuticals Inc (NASDAQ SYRS) opened at $9.47 on Friday. The company has a market capitalization of $291.68, a PE ratio of -4.71 and a beta of -2.36. Syros Pharmaceuticals Inc has a twelve month low of $6.30 and a twelve month high of $24.38.
Several equities analysts recently weighed in on the company. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 target price on the stock. in a research report on Saturday, January 20th. Oppenheimer set a $28.00 target price on Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, January 8th. HC Wainwright reiterated a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research report on Thursday, December 21st. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 target price on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. Syros Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $22.36.
A number of large investors have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals during the third quarter valued at about $240,000. Cubist Systematic Strategies LLC bought a new stake in Syros Pharmaceuticals during the third quarter valued at about $149,000. Schwab Charles Investment Management Inc. raised its holdings in Syros Pharmaceuticals by 95.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock valued at $614,000 after acquiring an additional 20,409 shares during the period. Citadel Advisors LLC bought a new stake in Syros Pharmaceuticals during the third quarter valued at about $975,000. Finally, Trexquant Investment LP bought a new stake in Syros Pharmaceuticals during the third quarter valued at about $282,000. 56.04% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Syros Pharmaceuticals Inc (SYRS) Director Buys $1,999,999.20 in Stock” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/04/syros-pharmaceuticals-inc-syrs-director-buys-1999999-20-in-stock.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.